U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H20FN3O4
Molecular Weight 337.3461
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LINEZOLID

SMILES

CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC=C(N3CCOCC3)C(F)=C2

InChI

InChIKey=TYZROVQLWOKYKF-ZDUSSCGKSA-N
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1

HIDE SMILES / InChI
Molecular Formula C16H20FN3O4
Molecular Weight 337.3461
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:45:32 UTC 2023
Edited
by admin
on Fri Dec 15 15:45:32 UTC 2023
Record UNII
ISQ9I6J12J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LINEZOLID
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
U-100766
Code English
LINEZOLID [USP-RS]
Common Name English
LINEZOLID [USAN]
Common Name English
LINEZOLID [MART.]
Common Name English
Linezolid [WHO-DD]
Common Name English
LINEZOLID [VANDF]
Common Name English
ZYVOX
Brand Name English
LINEZOLID [MI]
Common Name English
LINEZOLID [HSDB]
Common Name English
PNU-100766
Common Name English
LINEZOLID [ORANGE BOOK]
Common Name English
LINEZOLID [USP MONOGRAPH]
Common Name English
N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide
Systematic Name English
U-100,766
Code English
linezolid [INN]
Common Name English
LINEZOLID [JAN]
Common Name English
ACETAMIDE, N-((3-(3-FLUORO-4-(4-MORPHOLINYL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-, (S)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000007568
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
LIVERTOX NBK548245
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
NDF-RT N0000175495
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
NCI_THESAURUS C258
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
WHO-VATC QJ01XX08
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
WHO-ATC J01XX08
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
Code System Code Type Description
INN
7584
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
DRUG BANK
DB00601
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
DAILYMED
ISQ9I6J12J
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
NCI_THESAURUS
C29158
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
ChEMBL
CHEMBL126
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
FDA UNII
ISQ9I6J12J
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
EPA CompTox
DTXSID5046489
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
EVMPD
SUB08520MIG
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
CHEBI
63607
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
MERCK INDEX
m6829
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY Merck Index
RXCUI
190376
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY RxNorm
CAS
165800-03-3
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
SMS_ID
100000092506
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
MESH
C098010
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
RS_ITEM_NUM
1367561
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
PUBCHEM
441401
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
DRUG CENTRAL
1584
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
HSDB
7478
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
LACTMED
Linezolid
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
WIKIPEDIA
LINEZOLID
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
USAN
II-7
Created by admin on Fri Dec 15 15:45:32 UTC 2023 , Edited by admin on Fri Dec 15 15:45:32 UTC 2023
PRIMARY
Related Record Type Details
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
TARGET ORGANISM->INHIBITOR
Mycobacterium tuberculosis H37Rv
TARGET ORGANISM->INHIBITOR
MBC99
AMINE OXIDASE (FLAVIN-CONTAINING) A
METABOLIC ENZYME -> INHIBITOR
IC50
MYCOBACTERIUM TUBERCULOSIS
TARGET ORGANISM->INHIBITOR
Mycobacterium tuberculosis H37Rv
TARGET ORGANISM->INHIBITOR
MIC
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
STAPHYLOCOCCUS AUREUS
TARGET ORGANISM->INHIBITOR
AMINE OXIDASE (FLAVIN-CONTAINING) B
METABOLIC ENZYME -> INHIBITOR
Mycobacterium tuberculosis MDR Strains
TARGET -> INHIBITOR
Resistant rate 6.7%
MIC90
Mycobacterium tuberculosis XDR Strains
TARGET ORGANISM->INHIBITOR
Resistant rate 4.2%
MIC90
Related Record Type Details
Structure of LINEZOLID AMINE
METABOLITE -> PARENT
Accounted for less than 0.1% of the dose (Trace level). Presumed to involve N-acetyltransferase; reversible
Structure of PNU-173558
METABOLITE -> PARENT
PARTIAL AGONIST
FECAL; PLASMA; URINE
Structure of PNU-142586
METABOLITE INACTIVE -> PARENT
minor in plasma
MAJOR
FECAL; URINE
Structure of PNU-100440
METABOLITE -> PARENT
approximately 0.4 to 0.8% of the dose (trace level)
Structure of PNU-143010
METABOLITE -> PARENT
MINOR
Structure of ACETAMIDE, N-(((5S)-3-(3-FLUORO-4-((2-(2-HYDROXYETHOXY)ETHYL)AMINO)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-
METABOLITE -> PARENT
1% of dose
MINOR
Related Record Type Details
Structure of DEACETAMIDE LINEZOLID AZIDE
IMPURITY -> PARENT
Structure of N-(((5S)-3-(3-FLUORO-4-(4-MORPHOLINYL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)ETHANETHIOAMIDE
IMPURITY -> PARENT
Structure of 2-OXAZOLIDINONE, 5-((ACETYLOXY)METHYL)-3-(3-FLUORO-4-(4-MORPHOLINYL)PHENYL)-, (5R)-
IMPURITY -> PARENT
Structure of N-((2S)-3-AMINO-2-HYDROXYPROPYL)-N-(3-FLUORO-4-(MORPHOLIN-4-YL)PHENYL)ACETAMIDE
IMPURITY -> PARENT
Structure of BIS-LINEZOLID
IMPURITY -> PARENT
Structure of LINEZOLID DESCARBONYL N-DESACETYL IMPURITY
IMPURITY -> PARENT
Structure of LINEZOLID DESCARBONYL (±)- ISOMER
IMPURITY -> PARENT
Structure of R-LINEZOLID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LINEZOLID AMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LINEZOLID DESCARBONYL (R)-ISOMER
IMPURITY -> PARENT
Structure of (3-(3-FLUORO-4-MORPHOLINOPHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL METHANESULFONATE, (R)-
IMPURITY -> PARENT
Structure of DESFLUOROLINEZOLID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LINEZOLID N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of LINEZOLID
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC POPULATION: ADULTS

Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: FULL-TERM NEONATES ≥ 1 WEEK TO ≤ 28 DAYS

Volume of Distribution PHARMACOKINETIC POPULATION: INFANTS > 28 DAYS TO < 3 MONTHS

Biological Half-life PHARMACOKINETIC POPULATION: INFANTS > 28 DAYS TO < 3 MONTHS

Volume of Distribution PHARMACOKINETIC POPULATION: ADULTS

Volume of Distribution PHARMACOKINETIC POPULATION: INFANTS AND CHILDREN 3 MONTHS TO 11 YEARS

ORAL BIOAVAILABILITY PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: ADOLESCENTS

Volume of Distribution PHARMACOKINETIC POPULATION: ADOLESCENTS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC POPULATION: FULL-TERM NEONATES < 1 WEEK

Volume of Distribution PHARMACOKINETIC POPULATION: FULL-TERM NEONATES ≥ 1 WEEK TO ≤ 28 DAYS

Volume of Distribution PHARMACOKINETIC POPULATION: FULL-TERM NEONATES < 1 WEEK

Biological Half-life PHARMACOKINETIC POPULATION: FULL-TERM NEONATES < 1 WEEK

Volume of Distribution PHARMACOKINETIC POPULATION: PRETERM NEONATES < 1 WEEK

Vdss PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: INFANTS AND CHILDREN 3 MONTHS TO 11 YEARS

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966